SCHEMBL7050666

SCHEMBL7050666

CCN(C(=O)CC(NS(=O)(=O)c1ccccc1)c1ccc(OCC(=O)O)c(C(=O)O)c1)c1ccc(OC)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.40
GRK2 P25098 1/20 0.40
DUSP3 P51452 1/20 0.40
PTPN5 P54829 1/20 0.40
PTPN11 Q06124 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
KEAP1 Q14145 3/20 0.40
NFE2L2 Q16236 3/20 0.40
ALDH1A1 P00352 5/20 0.39
PTPN1 P18031 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MAPT P10636 1/20 0.38
CNR1 P21554 1/20 0.38
KMT2A Q03164 1/20 0.38
HCRTR1 O43613 1/20 0.38
HCRTR2 O43614 1/20 0.38
ATM Q13315 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.38
KDM4E B2RXH2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4650946 0.85 POLB (0.44) POLBGRK2DUSP3PTPN5PTPN11
SCHEMBL4650899 0.85 POLB (0.47) POLBGRK2DUSP3PTPN5PTPN11
SCHEMBL4651292 0.85 ATM (0.38) POLBGRK2DUSP3PTPN5PTPN11
SCHEMBL4651316 0.82 ALDH1A1 (0.48) POLBALDH1A1PTPN1KMT2AKDM4E
SCHEMBL4650872 0.81 ALDH1A1 (0.60) POLBALDH1A1PTPN1SMN1; SMN2KMT2A
SCHEMBL7050019 0.79 ALDH1A1 (0.54) POLBALDH1A1PTPN1KMT2A
SCHEMBL7053662 0.76 ALDH1A1 (0.47) POLBALDH1A1KMT2AKDM4E
SCHEMBL4650884 0.76 PTPN1 (0.49) ALDH1A1PTPN1ATML3MBTL1
SCHEMBL4651379 0.75 ALDH1A1 (0.58) POLBALDH1A1PTPN1SMN1; SMN2MAPT
SCHEMBL4651111 0.74 ALDH1A1 (0.41) POLBALDH1A1PTPN1CNR1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6586467-B2 Tyrosine phosphatase inhibitors useful in the treatment or prevention of Type II Diabetes Mellitus ARRAY BIOPHARMA INC. 2003-07-01 US claimed
EP-1301474-A2 TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS Array Biopharma Inc. (US) 2003-04-16 EP claimed
US-20020040003-A1 Preparation of phosphatase inhibitors ARRAY BIOPHARMA INC. 2002-04-04 US claimed
WO-2002004412-A2 TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2002-01-17 WO claimed
US-6586467-B2 Tyrosine phosphatase inhibitors useful in the treatment or prevention of Type II Diabetes Mellitus ARRAY BIOPHARMA INC. 2003-07-01 US disclosed
US-20020040003-A1 Preparation of phosphatase inhibitors ARRAY BIOPHARMA INC. 2002-04-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020040003-A1 Preparation of phosphatase inhibitors PTPRS, PTPRO, PTPRR POLB 3603/4885GRK2 1143/4885DUSP3 50/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.